Temporal course of cognitive and behavioural changes in motor neuron diseases.
ALS
C9ORF
COGNITION
FRONTOTEMPORAL DEMENTIA
MOTOR NEURON DISEASE
Journal
Journal of neurology, neurosurgery, and psychiatry
ISSN: 1468-330X
Titre abrégé: J Neurol Neurosurg Psychiatry
Pays: England
ID NLM: 2985191R
Informations de publication
Date de publication:
12 Oct 2023
12 Oct 2023
Historique:
received:
20
04
2023
accepted:
06
09
2023
medline:
13
10
2023
pubmed:
13
10
2023
entrez:
12
10
2023
Statut:
aheadofprint
Résumé
Cognitive and behavioural dysfunction may occur in people with motor neuron disease (MND), with some studies suggesting an association with the Participants with MND were recruited through the Phenotype-Genotype-Biomarker study. Every 3-6 months, the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) was used to assess amyotrophic lateral sclerosis (ALS) specific (executive functioning, verbal fluency, language) and ALS non-specific (memory, visuospatial) functions. Informants reported on behaviour symptoms via semi-structured interview. Participants with neuropsychological data at ≥3 visits were included (n=237, mean age=59, 60% male), of which 18 (8%) were In this study, cognitive dysfunction was less common than previously reported and remained stable over time for most. However, cognition declines longitudinally in a small subset, which is not entirely related to
Sections du résumé
BACKGROUND
BACKGROUND
Cognitive and behavioural dysfunction may occur in people with motor neuron disease (MND), with some studies suggesting an association with the
METHODS
METHODS
Participants with MND were recruited through the Phenotype-Genotype-Biomarker study. Every 3-6 months, the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) was used to assess amyotrophic lateral sclerosis (ALS) specific (executive functioning, verbal fluency, language) and ALS non-specific (memory, visuospatial) functions. Informants reported on behaviour symptoms via semi-structured interview.
RESULTS
RESULTS
Participants with neuropsychological data at ≥3 visits were included (n=237, mean age=59, 60% male), of which 18 (8%) were
CONCLUSIONS
CONCLUSIONS
In this study, cognitive dysfunction was less common than previously reported and remained stable over time for most. However, cognition declines longitudinally in a small subset, which is not entirely related to
Identifiants
pubmed: 37827570
pii: jnnp-2023-331697
doi: 10.1136/jnnp-2023-331697
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Volkan Granit
(V)
John Ravits
(J)
Lauren Elman
(L)
Jaya Trivedi
(J)
Andrea Swenson
(A)
Eric Pioro
(E)
Jonathan Katz
(J)
James Caress
(J)
Samuel Maiser
(S)
Yuen So
(Y)
Jeannine Heckmann
(J)
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: JS reports grants from National Institute of Health (NIH), Facioscapulohumeral Muscular Dystrophy (FSHD) Society, Friends of FSH Research, and Muscular Dystrophy Association (MDA) and is a consultant or on the advisory board for Dyne, Avidity, Fulcrum and Sarepta. JW reports grants from the National Institutes of Health and the ALS Association. MB reports grants from the National Institutes of Health, the Muscular Dystrophy Association, and the ALS Association; as well as consulting fees for Alector, Alexion, Annexon, Arrowhead, Biogen, Cartesian, Denali, Eli Lilly, Horizon, Immunovant, Novartis, Roche, Sanofi, Takeda, UCB and UniQure. The University of Miami has licensed intellectual property to Biogen to support design of the ATLAS study.